Publication Name	World Journal of Diabetes
Manuscript ID	8064
Country	United States

Received	2013-12-15 08:45
Peer-Review Started	2013-12-15 10:13
To Make the First Decision	2014-02-13 15:57
Return for Revision	2014-02-17 18:40
Revised	2014-02-25 04:41
Second Decision	2014-03-12 18:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-03-12 18:45
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-04-11 09:53
Publish the Manuscript Online	2014-04-18 11:34

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Topic Highlights
Article Title	Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease
Manuscript Source	Invited Manuscript
All Author List	Luis R Lopez, Kirk E Guyer, Ignacio Garcia De La Torre, Kelly R Pitts, Eiji Matsuura and Paul RJ Ames
Funding Agency and Grant Number	Funding Agency Grant Number Senit Foundation, Scotland (United Kingdom) grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (Japan)
Corresponding Author	Luis R Lopez, MD, Corgenix Medical Corporation, 11575 Main Street, # 400, Broomfield, CO 80020, United States. llopez@corgenix.com
Key Words	Diabetes; Cardiovascular disease; Platelets; Thromboxane; Aspirin
Core Tip	The effect of aspirin (ASA) on platelet thromboxane (11dhTxB2) generation in diabetes (DM) and symptomatic cardiovascular disease (CVD) was reviewed. Consistent with a heightened platelet hyperactive background, baseline 11dhTxB2 was significantly higher in DM and acute coronary syndrome (ACS) than healthy individuals. ASA ingestion inhibited 11dhTxB2 in all subjects, but there were more ASA poor-responders (ASA “resistant”) in DM (14.8%) and ACS (28.7%) than controls (8.4%). Only post-ASA 11dhTxB2 levels predicted adverse cardiovascular outcomes. ASA poor-responders had higher isoprostane (8-isoPGF2?) levels suggesting an underlying systemic oxidative inflammatory process not affected by ASA that may maintain platelet hyperactivity in DM and atherothrombotic CVD.
Publish Date	2014-04-18 11:34
Citation	Lopez LR, Guyer KE, Garcia De La Torre I, Pitts KR, Matsuura E, Ames PRJ. Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes 2014; 5(2): 115-127
URL	http://www.wjgnet.com/1948-9358/full/v5/i2/115.htm
DOI	http://dx.doi.org/10.4239/wjd.v5.i2.115

Full Article (PDF)	WJD-5-115.pdf
Full Article (Word)	WJD-5-115.doc
Manuscript File	8064-Review.doc
Answering Reviewers	8064-Answering reviewers.pdf
Copyright License Agreement	8064-Copyright assignment.pdf
Peer-review Report	8064-Peer review(s).pdf
Scientific Editor Work List	8064-Scientific editor work list.doc